Clinical Trials Directory

Trials / Unknown

UnknownNCT05637983

Ultrasound-guided Femoral Puncture to Reduce Access- Related Complications After TAVR: (ACCESS-TAVR SIRIO)

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
508 (estimated)
Sponsor
Fondazione Toscana Gabriele Monasterio · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Recent observational data showed a marked reduction of vascular and bleeding complications by the use of ultrasound(US)-guided femoral artery puncture to gain the vascular access and guide the implantation of the Perclose ProGlide® vascular closure system. We aimed to compare in a 1:1 randomized fashion the effect of US-guided femoral puncture and Perclose ProGlide® implantation optimization vs fluoroscopy-guided puncture followed by Perclose ProGlide/ ProStyle implantation (standard approach) during TAVR.

Detailed description

Transfemoral approach has become the standard route for a transcatheter aortic valve replacement (TAVR) procedure. Despite the technology improvements, vascular complications and access-related bleeding are frequently observed after TAVR and emerge predominantly within 30 days after TAVR. Recent observational data showed a marked reduction of vascular and bleeding complications by the use of ultrasound(US)- guided femoral artery puncture to gain the vascular access and guide the implantation of the Perclose ProGlide® vascular closure system. We aimed to compare in a 1:1 randomized fashion the effect of US-guided femoral puncture and Perclose ProGlide® implantation optimization vs fluoroscopy-guided puncture followed by Perclose ProGlide/ ProStyle implantation (standard approach) during TAVR.

Conditions

Interventions

TypeNameDescription
PROCEDUREUS-guided femoral puncture vs Fluoroscopy-guided punctureUS-guided femoral puncture and Perclose ProGlide®/Prostyle implantation compared to Fluoroscopy-guided puncture and Perclose ProGlide®/Prostyle in TAVR

Timeline

Start date
2022-07-04
Primary completion
2023-11-01
Completion
2023-12-01
First posted
2022-12-06
Last updated
2022-12-06

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT05637983. Inclusion in this directory is not an endorsement.